Spoken Alpha
ADC Therapeutics SA
ADC Therapeutics designs and commercializes antibody-drug conjugates (ADCs) for cancer treatment. The company's approved product, ZYNLONTA, treats relapsed or refractory diffuse large B-cell lymphoma and is being studied in earlier treatment lines and other lymphomas.
ADC Therapeutics SA is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $134.1M market cap.
ADCT beat consensus EPS by 0.4% in Q2 FY2026, reported Aug 12, 2026.
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ADCT.
$ curl https://api.spokenalpha.com/v1/companies/ADCTFAQ
Spoken Alpha indexes ADCT's earnings call transcripts at https://spokenalpha.com/companies/ADCT. Each call links to attributed speakers and parsed analyst Q&A. ADC Therapeutics SA's own investor relations page is at https://ir.adctherapeutics.com/.
ADC Therapeutics SA (ADCT) held its most recent earnings call on 2026-08-13, covering fiscal Q2 2026.
ADC Therapeutics SA (ADCT) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | $-0.11 | $-0.19 | +42.1% | $19.2M | — | — | EODHD |
| Q1 FY2026 | 2026-05-03 | $-0.21 | $-0.20 | -5.0% | $20.0M | — | — | EODHD |
| Q4 FY2025 | 2026-03-11 | $-0.04 | $-0.30 | +86.6% | $23.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-0.30 | $-0.36 | +16.7% | $16.4M | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.50 | $-0.48 | -4.2% | $18.8M | — | — | EODHD |
| Q1 FY2025 | 2025-05-04 | $-0.36 | $-0.41 | +13.1% | $23.0M | — | — | EODHD |
| Q4 FY2024 | 2025-03-26 | $-0.29 | $-0.41 | +29.3% | $16.9M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.42 | $-0.39 | -7.7% | $18.5M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-0.38 | $-0.46 | +17.4% | $17.4M | — | — | EODHD |
| Q1 FY2024 | 2024-05-05 | $-0.56 | $-0.56 | 0.0% | $18.1M | — | — | EODHD |
| Q4 FY2023 | 2024-03-12 | $-1.03 | $-0.50 | -100.0% | $16.8M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.58 | $-0.63 | +7.9% | $14.5M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-0.58 | $-0.57 | -1.8% | $19.3M | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-0.74 | $-0.67 | -10.4% | $19.0M | — | — | EODHD |
| Q4 FY2022 | 2023-02-27 | $-0.10 | $-0.05 | -100.0% | $69.8M | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $0.13 | $-0.10 | +100.0% | $76.3M | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-0.73 | $-0.76 | +4.0% | $17.3M | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $-0.22 | $-0.67 | +67.2% | $46.5M | — | — | EODHD |
| Q4 FY2021 | 2022-03-02 | $-0.45 | $-0.86 | +47.7% | $17.0M | — | — | EODHD |
| Q3 FY2021 | 2021-11-01 | $-0.59 | $-0.73 | +19.2% | $13.1M | — | — | EODHD |
Source: EODHD. ADCT reported actuals as published; sparse fields render as —.